

Rylaze™ (asparaginase *Erwinia chrysanthemi* (recombinant)- rywn) (Intramuscular)

Document Number: OHSU HEALTHSERVICES-0612

Last Review Date: 04/04/2022

Date of Origin: 08/03/2021

Dates Reviewed: 08/2021, 11/2021, 04/2022

I. Length of Authorization

Coverage will be provided for 6 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Rylaze 10 mg/0.5 mL solution in a SDV : 18 vials per 7 days

B. Max Units (per dose and over time) [HCPCS Unit]:

- 1,800 billable units (180 mg) per week

III. Initial Approval Criteria ^{1-3,5}

Coverage is provided in the following conditions:

- Patient is at least 1 month of age; **AND**

Universal Criteria

- Patient must not have a history of serious pancreatitis, thrombosis, or hemorrhagic events with prior L-asparaginase therapy; **AND**

Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) † Φ

- Used as a component of multi-agent chemotherapy; **AND**
- Used as a substitute for *E. coli*-derived asparaginase (e.g., pegaspargase) in cases of hypersensitivity (e.g., systemic allergic reactions or anaphylaxis) §

§ Definition of Hypersensitivity Reactions (CTCAE v5.0)^{5,6}

Allergic Reaction

- Grade 1: Systemic intervention not indicated
- Grade 2: Oral intervention indicated

<ul style="list-style-type: none"> - Grade 3: Bronchospasm; hospitalization for clinical sequelae; IV intervention indicated - Grade 4: Life-threatening consequences; urgent intervention indicated - Grade 5: Death <p>Anaphylaxis</p> <ul style="list-style-type: none"> - Grade 1 or 2: N/A - Grade 3: Symptomatic bronchospasm, with or without urticaria; parenteral intervention indicated; allergy-related edema/angioedema; hypotension - Grade 4: Life-threatening consequences; urgent intervention indicated - Grade 5: Death

† FDA Approved Indication(s); ‡ Compendia recommended indication(s); Ⓞ Orphan Drug

IV. Renewal Criteria ¹

Coverage can be renewed based upon the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease stabilization or improvement as evidenced by a complete response [CR] (i.e., morphologic, cytogenetic or molecular complete response CR), complete hematologic response or a partial response by CBC, bone marrow cytogenetic analysis, QPCR, or FISH; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include severe hypersensitivity reactions including anaphylaxis, pancreatitis, thrombosis, hemorrhage, hepatotoxicity, etc.

V. Dosage/Administration

Indication	Dose
All indications	<p>When replacing a long-acting asparaginase product, the recommended dosage of Rylaze is 25 mg/m² administered intramuscularly every 48 hours (e.g., every Monday, Wednesday, and Friday for a total of 6 doses to replace each dose of pegaspargase)</p> <ul style="list-style-type: none"> • Refer to the prescribing information for the long-acting asparaginase product to determine the duration of administration as a replacement therapy

VI. Billing Code/Availability Information

HCPCS Code:

- J9021 – Injection, asparaginase, recombinant, (rylaze), 0.1 mg; 1 billable unit = 0.1 mg

NDC(s):

- Rylaze 10 mg/0.5 mL solution in a SDV: 68727-0900-xx

VII. References

1. Rylaze [package insert]. Palo Alto, CA; Jazz Pharmaceuticals, Inc.; June 2021. Accessed March 2022.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Asparaginase Erwinia chrysanthemi (recombinant)-rywn. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed March 2022.
3. Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. *Cancer*. 2011 Jan 15; 117(2): 238–249.
4. Raetz EA, Salzer WL. Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia, *Journal of Pediatric Hematology/Oncology*: October 2010 - Volume 32 - Issue 7 - p 554-563 doi: 10.1097/MPH.0b013e3181e6f003
5. Maese L, Rau RE, Raetz EA, et al. A phase II/III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) who are hypersensitive to E. coli-derived asparaginases. DOI: 10.1200/JCO.2020.38.15_suppl.TPS7568 *Journal of Clinical Oncology* 38, no. 15_suppl
6. Lin T, Hernandez-Illas M, Rey A, Jenkins J, et al. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers. *Clin Transl Sci*. 2021 May;14(3):870-879. doi: 10.1111/cts.12947. Epub 2021 Mar 23.
7. Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. *Leuk Lymphoma* 2011;52;2237-2253.
8. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. NIH National Cancer Institute: Division of Cancer Treatment & Diagnosis – Cancer Therapy Evaluation Program. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes

ICD-10	ICD-10 Description
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes
C83.57	Lymphoblastic (diffuse) lymphoma, spleen
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites
C91.00	Acute lymphoblastic leukemia not having achieved remission
C91.01	Acute lymphoblastic leukemia, in remission
C91.02	Acute lymphoblastic leukemia, in relapse

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC